SCHEMBL5833835

SCHEMBL5833835

CCC(C)(C)C(=O)C(=O)N1CCCC1C(=O)NCCC(c1ccccc1)c1ccccc1

nearest known ligand 0.96

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 14/20 0.96

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5834087 0.98 FKBP1A (1.00) FKBP1A
SCHEMBL5834887 0.85 FKBP1A (0.88) FKBP1A
SCHEMBL5834377 0.83 FKBP1A (0.94) FKBP1A
SCHEMBL8796618 0.82 FKBP1A (0.96) FKBP1A
SCHEMBL7761797 0.82 FKBP1A (1.00) FKBP1A
SCHEMBL7757995 0.80 FKBP1A (1.00) FKBP1A
SCHEMBL4677088 0.80 FKBP1A (1.00) FKBP1A
SCHEMBL5834153 0.79 FKBP1A (0.66) FKBP1A
SCHEMBL4677091 0.78 FKBP1A (0.82) FKBP1A
SCHEMBL4680561 0.78 FKBP1A (0.66) FKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056935-B2 Rotamase enzyme activity inhibitors GPI NIL HOLDINGS, INC. (US) 2006-06-06 US disclosed
US-20020052410-A1 Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins GLIAMED, INC. 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052410-A1 Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins FKBP14, FKBP1A, FKBP2 FKBP1A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.